Screening for prostate cancer using a new MRI method
ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol
This study is testing a new MRI method to see if it can better screen for serious prostate cancer in men aged 50-69 while reducing unnecessary tests and procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 50 Years to 69 Years |
| Sex | Male |
| Sponsor | Masaryk Memorial Cancer Institute Academic / other |
| Locations | 1 site (Brno, Czech Republic) |
| Trial ID | NCT05603351 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a biparametric MRI protocol for screening clinically significant prostate cancer in men aged 50-69. It involves a series of tests including serum PSA levels, MRI scans, and biopsies if necessary, all conducted under strict blinding to ensure unbiased results. The goal is to reduce the detection of non-significant cancers and improve the accuracy of prostate cancer screening. The study aims to establish a more effective screening method that minimizes unnecessary procedures and healthcare burdens.
Who should consider this trial
Good fit: Ideal candidates are men aged 50-69 with no prior prostate cancer diagnosis or recent PSA tests.
Not a fit: Patients with known prostate cancer, contraindications to MRI, or recent prostate biopsies will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate prostate cancer screenings, reducing unnecessary treatments and improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using MRI for prostate cancer detection, but this specific biparametric approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 50-69 years * Life expectancy over 10 years * Ability to undergo all planned procedures (without contraindications to MRI or biopsy) * No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction) * No PSA test or prostate MRI in the past 2 years. * No signs of prostatitis or urinary tract infection in the past 6 months. * Signed informed consent. Exclusion Criteria: * Contraindications to MRI * Hip replacement * Known BRCA1/BRCA2 mutation
Where this trial is running
Brno, Czech Republic
- Masaryk Memorial Cancer Institute — Brno, Czech Republic, Czechia (Recruiting)
Study contacts
- Principal investigator: Michal Staník, MD,PhD. — Masaryk Memorial Cancer Institute
- Study coordinator: Michal Standara, MD
- Email: standara@mou.cz
- Phone: 00420 543 136 008
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.